Rybelsus, the sister drug of the popular Type 2 diabetes drug Ozempic, reduces the risk of serious heart problems by 14 percent, manufacturer Novo Nordisk announced on Monday.
Novo Nordisk is also the maker of the injectable weight-loss drug Wegovy.
Ozempic’s Sister Drug Reduces Cardiovascular Risk by 14 Percent in Large-Scale Trial
Learn about the study’s possible impact on treatment strategies.
KK Stock/Shutterstock
George Citroner
Author
George Citroner reports on health and medicine, covering topics that include cancer, infectious diseases, and neurodegenerative conditions. He was awarded the Media Orthopaedic Reporting Excellence (MORE) award in 2020 for a story on osteoporosis risk in men.
